TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26862038

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 25157543

Group type: EXPERIMENTAL
Intervention: High protein and high cereal fiber diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Moderate protein and moderate cereal fiber diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low protein and low cereal fiber diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tailored dietary supplements for twice-daily consumption
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 22121190

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300 mg once daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400 mg twice daily)
Number of subjects: 39
Study: 21108824

Group type: EXPERIMENTAL
Intervention: Inter-Personal Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors
Number of subjects: 0
Study: 17418297

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous endothelial progenitor cells (EPCs) plus conventional therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0
Study: 16720149

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (MR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional sutures (CR)
Number of subjects: 20
Study: 14744170

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg b.i.d. for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 42
Study: 10735706

Group type: EXPERIMENTAL
Intervention: Continuous pulmonary perfusion during total cardiopulmonary bypass (perfused group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (control group)
Number of subjects: 30
Study: 8737145

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both doses of trovafloxacin
Number of subjects: 0
Study: 1524757

Group type: EXPERIMENTAL
Intervention: Ambulation after awakening
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ingestion of 10 mg nifedipine after awakening
Number of subjects: 26

Group type: COMPARATOR
Intervention: Remaining supine
Number of subjects: 26
Study: 2862057

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg b.d. for one week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31751607

Group type: EXPERIMENTAL
Intervention: Blue light exposure (30-min pulses daily for 6 weeks, peak λ = 469 nm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amber placebo light (30-min pulses daily for 6 weeks, peak λ = 578 nm)
Number of subjects: 32
Study: 30272379

Group type: EXPERIMENTAL
Intervention: Epiglottic catheter and nasal mask during physiology night
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard in-laboratory polysomnography
Number of subjects: 28
Study: 27776201

Group type: EXPERIMENTAL
Intervention: Multistrategy inference intervention (explicit instruction in 4 inference strategies)
Number of subjects: 66
Study: 26542467

Group type: EXPERIMENTAL
Intervention: Subjective Vitality Scale (SVS)
Number of subjects: 439
Study: 23490474

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus followed by infusion of 0.0625-0.250 μg/kg/min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fentanyl (2 μg/kg intravenously followed by infusion of 0.03-0.06 μg/kg/min)
Number of subjects: 17
Study: 21376434

Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with high phenolic content (366 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with medium phenolic content (164 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with low phenolic content (2.7 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no olive oil intervention)
Number of subjects: 200
Study: 19515553

Group type: EXPERIMENTAL
Intervention: Canfosfamide (CAN) 1000 mg/m(2) IV q 3 weeks
Number of subjects: 461

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m(2) IV q 4 weeks
Number of subjects: 461

Group type: COMPARATOR
Intervention: Topotecan (TOPO) 1.5 mg/m(2) IV d1-5 q 3 weeks
Number of subjects: 461
Study: 17529848

Group type: EXPERIMENTAL
Intervention: Assessment of mainstream performance (AMP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SIFTER instruments
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Reynell and Schlichting tests
Number of subjects: 26
Study: 15048739

Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection (LCR)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Open colonic resection (OCR)
Number of subjects: 210
Study: 11555521

Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment (7‐min infusion of adenosine, total 650 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30
Study: 9777976

Group type: EXPERIMENTAL
Intervention: 30 microg/g becaplermin gel
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: 100 microg/g becaplermin gel
Number of subjects: 922

Group type: COMPARATOR
Intervention: becaplermin gel
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 922

Group type: COMPARATOR
Intervention: Good ulcer care alone
Number of subjects: 922
Study: 7931184

Group type: EXPERIMENTAL
Intervention: VCA-IgG avidity determination
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: EA-IgG avidity determination
Number of subjects: 105
Study: 3653052

Group type: EXPERIMENTAL
Intervention: CBZ-controlled release (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional carbamazepine (CBZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmedication control group
Number of subjects: 0
Study: 31665507

Group type: EXPERIMENTAL
Intervention: Exercise and education plus cervico‐mandibular manual therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercise and education alone
Number of subjects: 61
Study: 30982940

Group type: EXPERIMENTAL
Intervention: Ongoing feedback during a 12-month maintenance walking program (telephone calls, biofeedback via pedometer, progressive goal setting)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care group (no feedback)
Number of subjects: 86
Study: 28079566

Group type: EXPERIMENTAL
Intervention: Multimodal system (SAFERsleep)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 40
Study: 26318558

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: SQ-109
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both Rifampicin and SQ-109 combined
Number of subjects: 86
Study: 23636235

Group type: EXPERIMENTAL
Intervention: Weight change after 1 month of ART
Number of subjects: 3389

Group type: EXPERIMENTAL
Intervention: Weight loss ≥2.5% at 1 month of ART
Number of subjects: 3389

Group type: EXPERIMENTAL
Intervention: Weight loss at 1 month of ART
Number of subjects: 3389
Study: 21757505

Group type: EXPERIMENTAL
Intervention: Low-similarity displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-similarity distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Similarity estimates from a computer vision model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cases where model and human rankings agreed
Number of subjects: 0
Study: 18836727

Group type: EXPERIMENTAL
Intervention: Aberration corrected hydrophilic acrylic intraocular lens (IOL) for MICS
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-piece hydrophobic acrylic IOL
Number of subjects: 0
Study: 16847681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.1 mg/70 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.2 mg/70 kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.4 mg/70 kg
Number of subjects: 12
Study: 15231917

Group type: EXPERIMENTAL
Intervention: Neighborhood Asthma Coalition (NAC) intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 249
Study: 12618922

Group type: EXPERIMENTAL
Intervention: Dronabinol (synthetic cannabinoid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabinoids (general)
Number of subjects: 0
Study: 10948356

Group type: EXPERIMENTAL
Intervention: Protein-bound polysaccharide (PSK)
Number of subjects: 751
Study: 8853263

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bismuth triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 0
Study: 1333740

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4014120

Group type: EXPERIMENTAL
Intervention: Random-zero sphygmomanometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer
Number of subjects: 0
Study: 30921552

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300g/d containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular yogurt (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300g/d)
Number of subjects: 44
Study: 28858387

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day plus atorvastatin 40 mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 65
Study: 27294589

Group type: EXPERIMENTAL
Intervention: Travoprost administered once daily to both eyes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bromfenac sodium hydrate administered twice daily to one eye
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flavin adenine dinucleotide sodium administered twice daily to the other eye
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (NSAID and control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: NSAID (Bromfenac sodium hydrate)
Number of subjects: 28
Study: 25240971

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg zinc/day for 8 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22846674

Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation (TKS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 20925938

Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18567436

Group type: EXPERIMENTAL
Intervention: Artequick (3.2 mg/Kg/day of artemisinin, 16 mg/Kg/day of piperaquine, and 0.16 mg/Kg/day of primaquine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: artesunate-mefloquine (4 mg/Kg/day of artesunate, 8 mg/Kg/day of mefloquine)
Number of subjects: 130
Study: 15838471

Group type: EXPERIMENTAL
Intervention: Patch angioplasty with polyester urethane (Vascular‐patch, B. Braun Medical AG)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 404
Study: 11864676

Group type: EXPERIMENTAL
Intervention: Q-tip test measuring straining angle
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: POP-Q system assessment at point Aa
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: POP-Q system assessment at point Ba
Number of subjects: 274
Study: 10668449

Group type: EXPERIMENTAL
Intervention: NPS 1506 (doses ranging from 5-100 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPS 1506 (neuroprotective doses of approximately 0.1-1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPS 1506 (100 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPS 1506 (doses producing behavioral toxicity)
Number of subjects: 0
Study: 7546487

Group type: EXPERIMENTAL
Intervention: Tripton used in conjunction with Opalux and the ultrafine compact-filled, experimental visible light cured resin composite M221784 (ICI Dental)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched restorations with the other resin composite)
Number of subjects: 0
Study: 2126739

Group type: EXPERIMENTAL
Intervention: High-dose Estramustine phosphate orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin C by i.v. injection every 6 weeks
Number of subjects: 0
Study: 7254509

Group type: EXPERIMENTAL
Intervention: Monaural presentation of single digits to right ear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monaural presentation of single digits to left ear
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dichotic presentation (not directly tested in this study)
Number of subjects: 0
Study: 31388698

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 35

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 35
Study: 28492196

Group type: EXPERIMENTAL
Intervention: Munident (herbal) dentifrice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard toothpaste
Number of subjects: 40
Study: 25588590

Group type: EXPERIMENTAL
Intervention: Continuous ultrasonic phacoemulsification with anterior chamber maintainer (ACM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous ultrasonic phacoemulsification without anterior chamber maintainer (ACM)
Number of subjects: 60
Study: 23121340

Group type: EXPERIMENTAL
Intervention: Aerodynamic drag (F(d)) measured during skiing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Energy dissipation (E(d))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mechanical modeling of drag coefficient
Number of subjects: 9
Study: 21635243

Group type: EXPERIMENTAL
Intervention: Lamotrigine (target 300 mg/day) + Atorvastatin 40 mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Phenytoin (target 4 mg/kg per day) + Atorvastatin 40 mg/day
Number of subjects: 119
Study: 19489707

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture points according to Traditional Chinese Medicine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fixed, standard acupuncture points
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham nonpenetrating acupuncture
Number of subjects: 31
Study: 16861717

Group type: EXPERIMENTAL
Intervention: Medical and surgical coronary disease treatments
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Increased treatment levels to reach 80% of eligible patients
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Maximizing treatment uptake of eligible heart failure patients
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Statins and secondary prevention therapies
Number of subjects: 1950
Study: 15272110

Group type: EXPERIMENTAL
Intervention: Melissa officinalis 600 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Melissa officinalis 300 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11458050

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: BCG plus isoniazid
Number of subjects: 957

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 957
Study: 9567003

Group type: EXPERIMENTAL
Intervention: Processed carrots and spinach
Number of subjects: 8

Group type: COMPARATOR
Intervention: Raw carrots and spinach
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Processed vegetables
Number of subjects: 8
Study: 8049912

Group type: EXPERIMENTAL
Intervention: Polyglyconate (Maxon)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 100
Study: 2845564

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (30 mg/kg/d) for one week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19488540

Group type: EXPERIMENTAL
Intervention: 0.5% Bupivacaine with 1:200,000 epinephrine
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0.5% Ropivacaine
Number of subjects: 37
Study: 573564

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Domperidone (5 or 10 mg)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 185
Study: 30685496

Group type: EXPERIMENTAL
Intervention: Workshop conference recommendations
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Opportunities for scholarship
Number of subjects: 142
Study: 28073037

Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate (IAAC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ferrous fumarate (FF)
Number of subjects: 150
Study: 27647061

Group type: EXPERIMENTAL
Intervention: AR+IVR
Number of subjects: 898

Group type: COMPARATOR
Intervention: UC
Number of subjects: 898
Study: 24418359

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 142
Study: 23062232

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) - S-1 40 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX) - capecitabine 1000 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX)
Number of subjects: 340
Study: 19548076

Group type: EXPERIMENTAL
Intervention: L-propionyl-carnitine (LPC) 1.2 g/day + PGE-1 60 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: PGE-1 only
Number of subjects: 75
Study: 17447874

Group type: EXPERIMENTAL
Intervention: Simultaneous intervention (both physical activity and fat intake interventions at baseline)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Sequential intervention (physical activity first, then fat intake 3 months later)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Sequential intervention (fat intake first, then physical activity 3 months later)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Overall interventions (both modes)
Number of subjects: 392
Study: 12699520

Group type: EXPERIMENTAL
Intervention: 10 micro g of sufentanil + 500 micro g of adenosine
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10 micro g of sufentanil
Number of subjects: 25
Study: 10895027

Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (5 mg), repeated if necessary
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate
Number of subjects: 60
Study: 8826608

Group type: COMPARATOR
Intervention: Daily oral etoposide alone for 21 days (arm A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Daily oral etoposide for 21 days with GM‐CSF, 250 micrograms/m2, s.c. twice daily for the first 10 days of etoposide administration (arm B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Daily oral etoposide for 21 days with GM‐CSF twice daily for the sixth through second days preceding etoposide administration (arm C)
Number of subjects: 39
Study: 1360464

Group type: EXPERIMENTAL
Intervention: Cilest (ethinyl estradiol 35 micrograms and norgestimate 250 mg) for 21 days, followed by 1-4 days of missed pills depending on the group.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no missed pills)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Group 2a (missed 1 day on day 6)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Group 3a (missed 3 days on day 18)
Number of subjects: 47
Study: 4072647

Group type: EXPERIMENTAL
Intervention: Thornton nail
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Scand hip pins
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Impaction by hammer
Number of subjects: 94

Group type: COMPARATOR
Intervention: No impaction
Number of subjects: 94
Study: 30891813

Group type: EXPERIMENTAL
Intervention: hCG/hMG for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 0
Study: 28795880

Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST), used four times daily for 20 minutes per session
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo control (no electric stimulation therapy)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST)
Number of subjects: 23
Study: 26053726

Group type: EXPERIMENTAL
Intervention: (68)Ga DOTATATE PET/CT
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conservative therapy (for patients with negative scans)
Number of subjects: 54
Study: 23580456

Group type: EXPERIMENTAL
Intervention: 70 ml nitrate‐rich concentrated beetroot juice (BR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tomato juice (placebo [PLA])
Number of subjects: 8
Study: 21135862

Group type: COMPARATOR
Intervention: Pharmacological treatment (Ph)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Osteopathic treatment (Os)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination of pharmacological and osteopathic treatment (PhO)
Number of subjects: 47
Study: 19474795

Group type: EXPERIMENTAL
Intervention: Midodrine (7.5-15 mg per day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 17373905

Group type: EXPERIMENTAL
Intervention: PANVAC™ cancer vaccine therapy delivered through recombinant vaccinia and recombinant fowlpox vectors, injected subcutaneously.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANVAC™ in combination with conventional chemotherapy and/or radiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANVAC™ alone.
Number of subjects: 0
Study: 15466063

Group type: EXPERIMENTAL
Intervention: Intervention group (clinicians saw the screening test results and a telephone-based parenting education program was available)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (clinicians did not see the screening test results)
Number of subjects: 224
Study: 11588322

Group type: EXPERIMENTAL
Intervention: UFH 12 500 IU SC BID
Number of subjects: 3169

Group type: EXPERIMENTAL
Intervention: UFH 5000 IU SC BID
Number of subjects: 3169

Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 3169